1050500-41-8

Basic information

• Product Name: PEG13-Tos
• Synonyms: PEG13-Tos;PEG15-Tos;Tos-PEG12-OH
• CAS NO: 1050500-41-8
• Molecular Formula: C31H56O15S
• Molecular Weight: 700.83234
• Mol File: 1050500-41-8.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: PEG13-Tos(CAS DataBase Reference)
• NIST Chemistry Reference: PEG13-Tos(1050500-41-8)
• EPA Substance Registry System: PEG13-Tos(1050500-41-8)

Safety Data

• Hazardous Substances Data: 1050500-41-8(Hazardous Substances Data)

Usage

Description

PEG13-Tos is a PEG linker containing a hydroxyl group and a tosyl group, which is designed to enhance solubility in aqueous media and facilitate further derivatization or replacement with other reactive functional groups. The tosyl group serves as an excellent leaving group for nucleophilic substitution reactions, making PEG13-Tos a versatile and valuable component in various applications.

Uses

Used in Pharmaceutical Industry:
PEG13-Tos is used as a crosslinker for the synthesis of antibody-drug conjugates (ADCs). The hydrophilic PEG spacer increases the solubility of the ADCs in aqueous media, while the hydroxyl and tosyl groups allow for the attachment of therapeutic agents to antibodies, creating a targeted drug delivery system. This targeted approach can improve the efficacy of treatments and reduce side effects by delivering the drug directly to cancer cells.
Used in Chemical Synthesis:
PEG13-Tos is used as a versatile building block in chemical synthesis, particularly for the creation of biocompatible and hydrophilic molecules. The hydroxyl group enables further derivatization with other functional groups, while the tosyl group can be replaced in nucleophilic substitution reactions, allowing for the development of a wide range of molecules with specific properties and applications.
Used in Drug Delivery Systems:
In the field of drug delivery, PEG13-Tos is utilized as a component in the design and synthesis of novel drug carriers. The hydrophilic PEG spacer can improve the solubility and bioavailability of drugs, while the reactive functional groups facilitate the attachment of therapeutic agents to the carrier system. This can lead to enhanced drug delivery, improved therapeutic outcomes, and reduced side effects for patients.

Upstream product

• 6790-09-6 dodecaethylene glycol 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 1456708-45-4 3,6,9,12,15,18,21,24,27,30,33-undecaoxapentatriacontane-1,35-diyl bis(4-methylbenzenesulfonate) 

Relevant articles and documents

Organometallic Gold(III) Reagents for Cysteine Arylation

An efficient method for chemoselective cysteine arylation of unprotected peptides and proteins using Au(III) organometallic complexes is reported. The bioconjugation reactions proceed rapidly (5 min) at ambient temperature in various buffers and within a wide pH range (0.5-14). This approach provides access to a diverse array of S-aryl bioconjugates including fluorescent dye, complex drug molecule, affinity label, poly(ethylene glycol) tags, and a stapled peptide. A library of Au(III) arylation reagents can be prepared as air-stable, crystalline solids in one step from commercial reagents. The selective and efficient arylation procedures presented in this work broaden the synthetic scope of cysteine bioconjugation and serve as promising routes for the modification of complex biomolecules.

CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO

In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self- immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

The intermediate body of polyethylene glycol derivatives and manufacturing method

PROBLEM TO BE SOLVED: To provide a simple method for producing a production intermediate of a polyethylene glycol derivative, and further to provide a large number of compounds useful as effective components of an antitumor agent by virtue of the method. SOLUTION: A polyethylene glycol monoether compound represented by formula (1) (in the formula, R represents a hydrocarbon group that may contain a substituent, and n represents a positive integer) or its salt is produced by using a compound resulting from esterifying one hydroxy group alone of a polyethylene glycol compound with a p-toluenesulfonyl group. COPYRIGHT: (C)2010,JPOandINPIT